Literature DB >> 11190807

Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays.

A Rhodes1, B Jasani, A J Balaton, D M Barnes, E Anderson, L G Bobrow, K D Miller.   

Abstract

Immunohistochemical assays for estrogen receptors (ERs) and progesterone receptors (PRs) have not been surveyed for technical validity. In the present study, the reliability of the immunohistochemical assay for ER and PR was evaluated using data from 105 laboratories participating in external quality assessment (EQA) during a 2-year period. Technical variables associated with reliable immunostaining were analyzed. The efficiency of the antigen retrieval step was identified as the single most important contributory factor influencing the overall reproducibility of the assays. Reliable assays were found in 24 (36%) of 66 laboratories participating in continual EQA, including the majority of centers known to have clinically validated results. Inadequate assay sensitivity, with subsequent weak staining, was the main cause of poor and variable results by laboratories using microwave antigen retrieval; too short a heating time was identified as the principal contributory factor. Extension of the heating time resulted in significant improvement regardless of all other variables in the immunohistochemical protocol. Continual participation in EQA is an effective means for identifying and ameliorating variables that influence the reliability of immunohistochemical assays for predictive markers, thereby assisting in technical validation and standardization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11190807     DOI: 10.1309/H905-HYC1-6UQQ-981P

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

1.  Variation in rates of oestrogen receptor positivity in breast cancer again.

Authors:  Keith Miller; Anthony Rhodes; Bharat Jasani
Journal:  BMJ       Date:  2002-02-02

2.  Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.

Authors:  Kanwal P S Raghav; Leonel F Hernandez-Aya; Xiudong Lei; Marianan Chavez-Macgregor; Funda Meric-Bernstam; Thomas A Buchholz; Aysegul Sahin; Kim-Anh Do; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

3.  Microwave-triggered metal-enhanced chemiluminescence (MT-MEC): application to ultra-fast and ultra-sensitive clinical assays.

Authors:  Michael J R Previte; Kadir Aslan; Stuart Malyn; Chris D Geddes
Journal:  J Fluoresc       Date:  2006-09-02       Impact factor: 2.217

4.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.

Authors:  Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford A Hudis
Journal:  Oncologist       Date:  2010-11-01

5.  The effect of freezing on the immunoprofile of breast carcinoma cells.

Authors:  Asuman Argon; Alper Şener; Osman Zekioğlu; Murat Kapkaç; Necmettin Özdemir
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

Review 6.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.

Authors:  Zsolt Hodi; Jayeta Chakrabarti; Andrew H S Lee; John E Ronan; Christopher W Elston; Kwok Leung Cheung; John F R Robertson; Ian O Ellis
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

7.  Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer.

Authors:  Anastasios Dimou; Seema Agarwal; Valsamo Anagnostou; Hollis Viray; Stephen Christensen; Bonnie Gould Rothberg; Vassiliki Zolota; Konstantinos Syrigos; David L Rimm
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

8.  Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?

Authors:  Christopher Fosker; Julian W Adlard; Abeer Shaaban
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

9.  Experimental validation of peptide immunohistochemistry controls.

Authors:  Steven A Bogen; Kodela Vani; Brian McGraw; Vin Federico; Iqbal Habib; Ron Zeheb; Ed Luther; Colin Tristram; Seshi R Sompuram
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-05

10.  Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Authors:  Dominique Sighoko; Juxin Liu; Ningqi Hou; Paul Gustafson; Dezheng Huo
Journal:  Oncologist       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.